4D Molecular Therapeutics enrolls first patients in Phase 3 4SIGHT trial of 4D-150 for diabetic macular edema

By Public Technologies
  • 4D Molecular Therapeutics enrolled the first patients in 4SIGHT, a global Phase 3 trial of 4D-150 in treatment-naïve diabetic macular edema.
  • Updated two-year SPECTRA results were presented, supporting durable vision and anatomical improvements with reduced need for frequent injections.
  • The program advances 4D-150 into a second large retinal market, extending its late-stage pipeline beyond wet AMD.
  • Regulators have discussed a potential filing strategy that relies on this single DME Phase 3 study alongside prior DME and wet AMD data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280800PRIMZONEFULLFEED9834464) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.